A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-564
- Sponsors Merck Sharp & Dohme
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 06 Jul 2017 Status changed from not yet recruiting to recruiting.
- 09 May 2017 New trial record